Corcept Therapeutics
CORT
62 hedge funds and large institutions have $102M invested in Corcept Therapeutics in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 10 closing their positions.
264% more call options, than puts
Call options by funds: $91K | Put options by funds: $25K
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
11% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 19
5% more funds holding
Funds holding: 59 → 62 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
37% less capital invested
Capital invested by funds: $161M → $102M (-$59.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.25M |
| 2 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
+$1.59M |
| 3 |
ISL
Ingalls & Snyder LLC
New York
|
+$459K |
| 4 |
Goldman Sachs
New York
|
+$400K |
| 5 |
State Street
Boston,
Massachusetts
|
+$328K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$9.38M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.04M |
| 3 |
Millennium Management
New York
|
-$443K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$381K |
| 5 |
Barclays
London,
United Kingdom
|
-$335K |
CORT Hedge Fund Activity: Q2 2014 in Review
62 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q2 2014, worth a combined $102M — down 37% from $161M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CORT positions and 10 closed out — a net gain of 3 holders — while 21 added to existing stakes and 19 trimmed.
The largest buyer was Federated Hermes, adding an estimated $3.25M. The largest seller was Jennison Associates, exiting entirely with an estimated $9.38M sold.
- 62 institutional investors held Corcept Therapeutics (CORT) as of Q2 2014, up from 59 in Q1 2014.
- Funds reported $102M of Corcept Therapeutics stock for Q2 2014, down 37% quarter-over-quarter.
- 13 funds opened new Corcept Therapeutics positions in Q2 2014 and 10 closed out, a net change of +3 holders.
- The largest Corcept Therapeutics buyer in Q2 2014 was Federated Hermes, an estimated $3.25M added.
- The largest Corcept Therapeutics seller in Q2 2014 was Jennison Associates, an estimated $9.38M sold.
Based on aggregated 13F filings for Q2 2014.